Herring RA, Shojaee-Moradie F, Garesse R, Stevenage M, et al. Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136. Diabetes Care 2021;44:e61.
PMID: 33608329